The upcoming CarboHyde Cyclodextrin Masterclass will focus on the emerging role of cyclodextrins (CDs) as active pharmaceutical ingredients (APIs), highlighting how these versatile molecules are moving beyond their classical excipient role into the therapeutic spotlight. Through landmark examples such as Sugammadex, a CD-based neuromuscular blockade reversal agent, and hydroxypropyl-β-cyclodextrin (HPβCD) in the treatment of Niemann-Pick Type C disease, participants will gain insight into how the unique host–guest chemistry of CDs translates into clinical efficacy.
The session will further explore next-generation applications of CDs, including their use as scavengers for drug overdose, and their potential in new therapies for widespread conditions such as Alzheimer’s disease and atherosclerosis, as well as rare diseases including Kabuki syndrome and focal segmental glomerulosclerosis (FSGS). The discussion will cover mechanistic aspects—how CDs modulate biological pathways and molecular interactions—alongside chemical design strategies, drug discovery approaches, and regulatory and Chemistry–Manufacturing (CM) considerations essential for translation into approved therapies.
This Masterclass will provide researchers, developers, and industry professionals with a comprehensive perspective on cyclodextrins as therapeutic agents, bridging molecular innovation with real-world drug development challenges and opportunities.
Register now – before it’s too late to uncover how cyclodextrins are redefining therapeutics!
This time our flourishing GENEGUT collaboration produced a great paper on the SAR investigations of cyclodextrins in gene delivery.
This topic is essential to understand how cyclodextrins actually work when encapsulating different oligos and what are the ideal structures for the nanoparticle formation loading and transfection.
MOFs (Yaghi/Kitagawa/Robson; 2025 Nobel) provide the conceptual and practical foundation for porous, programmable materials.
Cyclodextrin-based MOFs translate that vision into renewable, water-grown frameworks ideal for encapsulation and delivery.
Stoddart’s OSMV™ technology carries supramolecular encapsulation into Noble Panacea’s skincare, echoing the CD-MOF ethos of protect–and-release for sensitive actives.
If you follow advanced materials, you’ve seen metal–organic frameworks (MOFs) go from academic curiosities to workhorses for gas capture, water harvesting, separations, catalysis—and, perhaps unexpectedly, skincare. This post traces that journey, with a special focus on the seminal roles of Omar M. Yaghi and Sir J. Fraser Stoddart, and how cyclodextrin-based MOFs helped inspire Noble Panacea, a luxury beauty brand built on Stoddart’s supramolecular chemistry.
What are MOFs—and why they matter
MOFs are crystalline scaffolds built by linking metal ions (or clusters) with organic ligands to create vast internal pore networks—imagine molecular Tinkertoys with football-field surface areas packed into a sugar cube. Over the last three decades, Yaghi, Kitagawa, and Robson established the foundations of the field, earning the 2025 Nobel Prize in Chemistry for MOFs’ design and impact. Their work enabled record porosities and practical functions like CO₂ capture and pulling water from desert air.
Enter cyclodextrins: edible rings as MOF building blocks
Cyclodextrins (CDs)—ring-shaped oligosaccharides derived from starch—are famous for hosting small molecules inside their hydrophobic cavities. The twist came when researchers realized that CDs could act as organic nodes in MOFs. By combining especially γ-cyclodextrin (eight glucose units) with benign alkali metals (K⁺, Rb⁺, Cs⁺, etc.), teams created cyclodextrin MOFs (CD-MOFs): renewable, biodegradable frameworks that crystallize from water and can store, separate, and release bioactives. Reviews now describe CD-MOFs as porous, renewable, and even “edible” materials with broad potential in pharma, food, and personal care.
A 2011 patent family laid out the concept explicitly—nanoporous carbohydrate frameworks built from cyclodextrins and alkali metals—with structures featuring large central pores (~1.7 nm) and smaller channels, ideal for guest uptake and release. Subsequent studies from Stoddart’s community showed molecular separations (terpenes, aromatics) and drug loading (e.g., ibuprofen) inside CD-MOF crystals.
Stoddart’s supramolecular route to skincare
Nobel laureate Sir Fraser Stoddart pioneered mechanically interlocked molecules and host–guest systems (cyclodextrins loom large in his toolkit). Building on that supramolecular platform, Stoddart co-developed OSMV™ (Organic Super Molecular Vessel)—a programmable delivery architecture designed to protect actives and time-release them where skin can best use them. Noble Panacea, the brand he founded, centers its formulations on OSMV technology, describing it as constructed from biodegradable carbohydrates and fatty acids, with vessels far smaller than a skin cell and “molecular-precision” delivery.
If you like these brief communications, subscribe to join 5100 cyclodextrin enthusiasts and gain and share knowledge on current and novel applications, challenges, and possibilities.
How does this tie to CD-MOFs? While Noble Panacea’s own materials emphasize OSMV as a proprietary supramolecular capsule platform, cyclodextrin-based porous materials are frequently cited in the broader narrative linking Stoddart’s academic advances to real-world encapsulation and release in cosmetics. Commentary within the cyclodextrin community has highlighted γ-CD MOFs as part of this lineage, and related patents from affiliated entities (e.g., PanaceaNano) cover fragrance/active delivery using CD-MOFs—underscoring a technical bridge from carbohydrate-MOFs to consumer delivery systems.
Bottom line: Whether the commercial OSMV capsules are literally CD-MOFs or an evolved, proprietary supramolecular construct, the design logic is shared: carbohydrate-based hosts assembling into porous or compartmentalized architectures that stabilize, protect, and program the release of sensitive actives.
Why CDs (and MOFs) make sense for beauty and biomedicine
Safety & sustainability: CDs are starch-derived and widely used in pharma/food; CD-MOFs inherit this favorable profile and can be crystallized from water with benign cations.
Stability & solubility: Encapsulation mitigates light/oxygen sensitivity and boosts the solubility of hydrophobic actives—critical for retinoids, peptides, and fragrances.
Programmable release: Framework pores/capsules enable staged, time-controlled delivery, aligning with circadian skincare claims (e.g., night serums tuned to skin rhythms).
Precision separations: On the industrial side, CD-MOFs separate complex mixtures—handy for purifying actives or tailoring fragrance accords.
The Yaghi effect: platform thinking
Yaghi’s MOF vision—reticular chemistry that assembles modular, predictable architectures—set the cultural blueprint for translating porous materials into real products (carbon capture, water harvesters, purification media). That platform mindset helped normalize the idea that frameworks built from everyday chemistries (even carbohydrates like CDs) can do sophisticated jobs in health, environment, and consumer goods—a through-line that runs from MOF-based water harvesters to elegant skin-delivery capsules.
Where this is heading
Cleaner INCI lists via smarter carriers: Expect more biodegradable, sugar-based hosts and MOF-inspired capsules to reduce stabilizers and solvents.
Personalized release kinetics: Tunable pore sizes/chemistries could match release profiles to individual skin needs, echoing pharma’s controlled-release playbook.
Fragrance & actives 2.0: Patented CD-MOF fragrance systems point toward longer-lasting scents and layered notes on skin—without heavy fixatives.
The Cyclodextrin Masterclass series has become a cornerstone for education and science communication in the field, fostering knowledge exchange and collaboration among researchers, students, and industry experts worldwide. Over its ten editions, it has helped bridge fundamental science and applied innovation, supporting the growth of the global cyclodextrin community and inspiring new generations of scientists.
As we approach the 10th edition, we invite researchers to present their cyclodextrin-related work in a 15-minute talk (10 min presentation and 5 min Q&A) at one of our upcoming Masterclasses.
If you’d like to share your research, please send a short abstract to tamas.sohajda@carbohyde.com.
This time our flourishing GENEGUT collaboration produced a great paper on the SAR investigations of cyclodextrins in gene delivery.
This topic is essential to understand how cyclodextrins actually work when encapsulating different oligos and what are the ideal structures for the nanoparticle formation loading and transfection.
Dr. Jozsef Szejtli, along with his early co-workers, pioneered techniques leading to the industrial application of CDs. Without Szejtli’s pioneering work, the CD industry would likely not be as advanced as it is today.
At CarboHyde, we are also building his legacy, as his daughter is helping us in human resources and his grandson is our CFO.
So we are the third-generation cyclodextrin innovators already.
